910-P: Novel Mechanism of Action Associated with SGLT2 Inhibition, Peripheral Energy Utilization, and CV Benefits in Subjects with Type 2 Diabetes Mellitus and HFrEF

Key Points

Key points are not available for this paper at this time.

Abstract

Background: SGLT2i is associated with CV benefits, but the mechanisms are not fully elucidated. We report a novel finding associated with improved CV Health in T2D 0.05) (Fig.1) Conclusion: We show for the first time that, in subjects with T2DM Novo Nordisk. Consultant; Eli Lilly and Company. Other Relationship; American Diabetes Association. G.D. Clarke: None. E. Cersosimo: None. R.A. DeFronzo: Advisory Panel; AstraZeneca, Novo Nordisk, Boehringer-Ingelheim, Intarcia Therapeutics, Inc., Aardvark, Renalytix, Corcept Therapeutics, Alnylam Pharmaceuticals, Inc. Research Support; Boehringer-Ingelheim, AstraZeneca, 89bio, Inc., Amgen Inc., Medality, Corcept Therapeutics. Speaker's Bureau; AstraZeneca, Corcept Therapeutics, Renalytix. C. Solis-Herrera: Advisory Panel; Novo Nordisk, Bayer Inc. Funding Doris Duke Foundation

Bookmark

Cite This Study

QIN et al. (Fri,) studied this question.

synapsesocial.com/papers/68e64c4bb6db6435875dd06a https://doi.org/https://doi.org/10.2337/db24-910-p

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1222-OR: Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Type 1 Diabetes: A Target Trial Emulation Study